SOLICITATION NOTICE
65 -- Influenza Vaccine
- Notice Date
- 7/8/2014
- Notice Type
- Justification and Approval (J&A)
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Medical, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
- ZIP Code
- 19111-5096
- Archive Date
- 8/1/2014
- Point of Contact
- Neil Mcavinue, Phone: 215-737-3126
- E-Mail Address
-
Neil.Mcavinue@dla.mil
(Neil.Mcavinue@dla.mil)
- Small Business Set-Aside
- N/A
- Award Number
- SPE2DP14C0002
- Award Date
- 7/2/2014
- Description
- 1. The Defense Logistics Agency (DLA) Troop Support, Medical Supplier Operations, is the contracting activity. 2. The action submitted for approval is the ability to solicit for DLA requirements on an other than full and open competition basis because of urgent requirements. 3. The acquisition is for Injectable Influenza Vaccine, for ages 18 years and up, in packages of 10 prefilled syringes (10 individual doses). A line for the federal excise tax for each package purchased is added to any resultant contract/order: [redacted] 4. The applicable statutory authority permitting other than full and open competition is 10 U.S.C. 2304(c)(2), FAR 6.302-2, Unusual and Compelling Urgency. 5. The use of this authority is necessary because the current supplier of the subject vaccine is unable to meet all the technical requirements of the vaccine. [redacted] The Government must secure an order by July 2, 2014 in order to meet the Services' required delivery time frames of 70% of quantity delivered by August 29, 2014 and the remaining quantity by September 30, 2014. 6. Due to the urgency of the requirement, a synopsis is not required in accordance with FAR 5.202(a)(2). We intend to solicit Novartis and BioCSL, who are known suppliers of the vaccine, can comply with all technical requirements, and can deliver within the Services' time frames. 7. As the Contracting Officer, I hereby determine that the anticipated cost to the Government will be fair and reasonable based on anticipated competition and comparison with the commercial pricing. 8. Novartis and BioCSL are the only known suppliers that have FDA approval for U.S. distribution and can meet the technical and delivery requirements. 9. In the absence of timely delivered vaccine, the Government faces real harm and expense associated with the disruption in vaccination scheduling of service members, including retirees and dependents. The cancellation and postponement of vaccination schedules will mean that service members will go unvaccinated for longer periods of time thereby risking infection and serious illness, resulting in reduction of manpower. 10. Novartis and BioCSL have expressed an interest in this acquisition. 11. This item is historically competitive. There are two potential sources for the proposed procurement. We anticipate future routine procurements for this item will be fully competitive. 12. The undersigned Contracting Officer hereby certifies that the information contained in this justification is accurate and complete to the best of his knowledge and belief. Date 7/1/2014 NEIL McAVINUE Contracting Officer
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/1789f4f9e7f68221deb295e048aabee0)
- Record
- SN03418131-W 20140710/140708235515-1789f4f9e7f68221deb295e048aabee0 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |